Deltex Medical Group PLC US launch of TrueVue(TM) system

TIDMDEMG

Deltex Medical Group PLC

24 October 2017

24 October 2017

Deltex Medical Group plc

("Deltex Medical" or "the Company")

US launch of TrueVue(TM) system

Deltex Medical Group plc (AIM: DEMG), the global leader in Oesophageal Doppler Monitoring ("ODM"), is pleased to announce the launch this week of its revolutionary concept in advanced haemodynamic monitoring, the TrueVue(TM) system.

The TrueVue(TM) system comprises three distinct best-in-class advanced haemodynamic monitoring technologies on a single platform (the CardioQ-ODM+):

 
      -   TrueVue(TM) Doppler: high-end ODM technology providing beat-to-beat 
           imaging of cardiac output for monitoring sedated patients and 
           easy calibration/recalibration of arterial pressure cardiac 
           output 
      -   TrueVue(TM) Impedance: non-invasive, high definition impedance 
           cardiography for monitoring awake patients, both mobile and 
           immobile 
      -   TrueVue(TM) Loops: unique real-time biomarkers for early detection 
           of hypo- and hyper-volaemia, hypo- and hyper-tension and real-time 
           display of responses to treatment 
 

The TrueVue(TM) system is being featured at Deltex's booth at Anesthesiology 2017, the annual meeting of the American Society of Anesthesiologists in Boston, MA. This is the largest anaesthesia conference in the USA and is attended by large numbers of international delegates as well as thousands of doctors from across the USA.

Use of TrueVue(TM) Impedance in the USA is subject to FDA approval: the submission (510K) has been submitted and not yet granted.

Ewan Phillips, Deltex Medical's Chief Executive, commented:

"The launch of the TrueVue(TM) system on the CardioQ-ODM+ platform is an exciting development for the Company. It means we will now be marketing the world's first haemodynamic monitoring system which can be used across the whole patient pathway from awake, mobile outpatients of all ages through to sedated, critical care patients. The TrueVue(TM) system can be used by trainee staff, in non-critical situations, through to experienced specialists. It will also broaden the Company's addressable market and positions us to supply hospitals with all their haemodynamic monitoring requirements on a single platform."

For further information, please contact:-

 
 Deltex Medical Group            01243 774 837 
  plc                             [e-mail] 
 Nigel Keen, Chairman 
 Ewan Phillips, Chief 
  Executive 
 Jonathan Shaw, Group 
  Finance Director 
 
 Nominated Adviser & 
  Broker 
 Arden Partners plc              020 7614 5900 
 Chris Hardie 
  Ciaran Walsh 
 
 Joint Broker 
 Turner Pope Investments         0203 621 4120 
  (TPI) Ltd                       [e-mail] 
 Andy Thacker 
 
   Financial Public Relations 
 IFC Advisory Ltd                0203 053 8671 
 Tim Metcalfe 
  Graham Herring 
  Heather Armstrong 
 

Notes for Editors

Deltex Medical manufactures and markets haemodynamic monitoring technologies. Deltex Medical's proprietary ODM is the only technology to measure blood flow in the central circulation in real time. Minimally invasive, easy to set up and quick to focus, the technology generates a low-frequency ultrasound signal, which is highly sensitive to changes in flow and measures them immediately. Deltex has been the only company in the enhanced haemodynamic space to build a robust and credible evidence base proving the clinical and economic benefits of its core technology, ODM which is proven to reduce complications suffered by patients after surgery and save hospitals the costs of treating those complications.

Deltex Medical's CardioQ-ODM+ platform also now provides clinicians with two further advanced haemodynamic monitoring technologies. High Definition Impedance Cardiography is an entirely non-invasive monitoring technology which creates an electrical field across the chest and measures the disruption to this field when the heart pumps blood. Pulse Pressure Waveform Analysis uses peripheral blood pressure signal analysis to give doctors information on changes in the circulation and is particularly suited to monitoring lower risk or haemodynamically stable patients.

Company goal

Haemodynamic management is now becoming widely accepted as an important major new medical modality. Consequently, the Company's focus is on maximising value from the opportunities presented as enhanced haemodynamic management is adopted into routine clinical practice around the world. The Company aims to provide clinicians with a single platform, a 'haemodynamic workstation', which offers them a range of technologies from simple to sophisticated to be deployed according to the patient's condition and skill and expertise of the user. Doing this will enable the Company to partner healthcare providers to support modern haemodynamic management across the whole hospital.

The Company is currently in the implementation phase of achieving this goal in a number of territories worldwide, operating directly in the UK, USA, Spain and Canada and through distribution arrangements in a further 30 countries.

There are over 3,400 monitors installed in hospitals around the world and around 700,000 patients have been treated to date using Deltex Medical's single patient disposable products.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRAEASEDALXXFFF

(END) Dow Jones Newswires

October 24, 2017 02:00 ET (06:00 GMT)